Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Jack Russell who wrote (11915)	5/13/2013 7:08:14 AM
From: NTTG	2 Recommendations Respond to of 13111

Not at all, Had they published their PII results in a peer reviewed Journal so we could all see the data I would have been happier Had they decided to start developing their MOA story years ago I would have been very happy Had they done a head to head comparison in human or animal models to validate their arguments I would have been giddy Had they stuck with a focused R&D program and not tried to get into 'every cancer under the sun' I would have been ecstatic Had they presented a realistic appraisal of their prospects for investors I would have been speechless (which I presume is your ultimate goal here) But Instead they have tried to do research on the cheap (in all possible interpretations), and continue to try to spin their story well beyond the bounds of clinical and scientific reality...priceless investment opportunity for sure, but sad for many in the end Trying to shoot the messenger gets you no where..... So tell us Jack, do you think they should be at ASCO on the cusp of their PIII trial?